Kadmus Pharmaceuticals

About:

Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics.

Top Investors: EDBI, Sanderling Ventures, Gray Ghost Ventures, VenGrowth Asset Management, NeuroVentures

Description:

Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics. Endocannabinoids are naturally occurring signaling molecules, whose functions include regulating mood, pain, and metabolism. It offers a portfolio of compounds with activity against a range of disorders targeting CNS conditions, metabolic disorders, neuropathic pain, and obesity. The company develops products for various conditions through the inhibition of endocannabinoid degradation and activation of endocannabinoid related pathways and peripheral cannabinoid receptors. It operates in the United States, Canada, and Europe. Kadmus Pharmaceuticals, Inc. was founded in 1998 and is based in Irvine, California.